Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 152 of the 154 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To formulate clinical practice guidelines for the pharmacological management of obesity. PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. This guideline was co-sponsored by the European Society of Endocrinology and The Obesity Society. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of the Endocrine Society, the European Society of Endocrinology, and The Obesity Society reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize some of the supporting evidence. CONCLUSIONS: Weight loss is a pathway to health improvement for patients with obesity-associated risk factors and comorbidities. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone. Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medications, choosing whenever possible those with favorable weight profiles, can aid in the prevention and management of obesity and thus improve health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In contrast, the National Institute for Health and Clinical Excellence (NICE) [37], Endocrine Society [35], and American College of Cardiology [36] uniformly recommend using only licensed medications for weight management and did not consider off-label options such as metformin.”
From A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis. (2022) · cites this paper as [35]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The STEP 1, 3, and 4 trials used semaglutide in conjunction with a lifestyle program and resulted in 16.9% to 18.2% weight-loss (using a completers-type analysis), which is superior to phase 3 trial results for other weight-loss medications, though without head-to-head drug comparison.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [759]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commonly prescribed medications such as antidepressants (eg, mirtazapine, amitriptyline) and antihyperglycemics such as glyburide or insulin cause weight gain, and clinicians should review and consider alternatives.”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consideration of individual food preferences, cultural traditions, and budgetary requirements may aid in the adherence to healthy dietary patterns, a key predictor of success [42,45].”
From Nutritional considerations with antiobesity medications (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medication classes promoting weight gain include antihyperglycemics (eg, glyburide, insulin), antidepressants (eg, amitriptyline, mirtazapine), antipsychotics (eg, olanzapine, quetiapine), antiepileptics (eg, gabapentin, carbamazepine), β-blockers, progesterone-based contraceptives, corticosteroids, and antiretroviral therapy (eg, protease inhibitors).12,77”
From Obesity Management in Adults: A Review (2023) · cites this paper as [12]
Experimental — accuracy not yet measured
29 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“The AHA/ ACC/TOS Guideline for the Management of Overweight and Obesity in Adults reviewed randomized clinical trials on weight loss interventions and determined that the best weight loss outcomes occur with frequent face-to-face visits (16 visits per year on average) (8, 38).”
BackgroundGrading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in the development and implementation of evidence-based guidelines (1).”
MethodOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“obese are at increased risk for many malignancies (7).”
BackgroundDecision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citationNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551 · cited 1×
“T2DM Yes Cohen, 2012 (132); Mingrone, 2012 (133); Schauer, 2012 (134); Buchwald, 2009 (135) Hypertension Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Dyslipidemia and metabolic syndrome Yes Ilane-Parikka, 2008 (136); Phelan, 2007 (137); Zanella, 2006 (138) Cardiovascular disease Yes Wannameth…”
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“GLP-1 agonists also affect the POMC neurons and cause satiety (18).”
Background
Research works printed but not linked: 15
- [3]3. DomecqJP,PrutskyG,LeppinA,etal. Drugscommonlyassociated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab . 2015;100:363-370.
- [11]11. Goldsmith R, Joanisse DR, Gallagher D, et al. Effects of experimentalweightperturbationonskeletalmuscleworkefficiency,fuel utilization, and biochemistry in human subjects. Am J Physiol Regul Integr Comp Physiol . 2010;298:R79-R88.
- [19]19. Stahl SM. Impulsivity, compulsivity, and addiction. In: Stahl's Essential Psychopharmacology . 4th ed. New York, NY: Cambridge University Press; 2013:537-575.
- [22]22. Mendieta-ZerónH,LópezM,DiéguezC. Gastrointestinalpeptides controlling body weight homeostasis. Gen Comp Endocrinol . 2008;155:481-495.
- [35]35. Avenell A, Brown TJ, McGee MA, et al. Whatinterventions should weaddtoweightreducingdietsinadultswithobesity?Asystematic review of randomized controlled trials of adding drug therapy, exercise, behaviourtherapyorcombinationsoftheseinterventions. J Hum Nutr Diet . 2004;17:293-316.
- [68]68. Grandy S, Hashemi M, Langkilde AM, Parikh S, Sjöström CD. Changesinweightloss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab . 2014;16:645-650.
- [79]79. Greenway FL, Fujioka K, Plodkonski RA, et al. COR I Study Group. Lancet . 2010;376:595-605.
- [82]82. Jacob AN, Salinas K, Adams-Huet B, Raskin P. Weightgainintype 2 diabetes mellitus. Diabetes Obes Metab . 2007;9:386-393.
- [88]88. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain duringinsulintherapywithandwithoutmetformininpatientswith type II diabetes mellitus. Diabetologia . 1999;42:406-412.
- [95]95. WingLM,ReidCM,RyanP,etal. Acomparisonofoutcomeswith angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med . 2003;348:583-592.
- [110]110. MaayanL,CorrellCU. Weightgainandmetabolicrisks associated withantipsychoticmedicationsinchildrenandadolescents. J Child Adolesc Psychopharmacol . 2011;21:517-535.
- [126]126. Boers M, van der Heijde DM. Prevention or retardation of joint damageinrheumatoidarthritis:issuesofdefinition,evaluationand interpretation of plain radiographs. Drugs . 2002;62(12):17171724.
- [128]128. Aronne LJ. Drug-induced weight gain: non-CNS medications. In: Aronne LJ, ed. A Practical Guide to Drug-Induced Weight Gain . Minneapolis, MN: McGraw-Hill; 2002:77-91.
- [14]14. tional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol . 2005;100:1072-1081.
- [146]146. Huang MH, Chen CH, Chen TW, Weng MC, Wang WT, Wang YL. Theeffectsofweightreductionontherehabilitationofpatients with knee osteoarthritis and obesity. Arthritis Care Res . 2000;13: 398-405.
Cited by
Items 401–500 of 1,001
Lyu, B., Chang, A. R., Inker, L. A., Selvin, E., Grams, M. E., & Shin, J.-I. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100249 · Cited by 22
Xue, Y., Zou, H., Ruan, Z., Chen, X., Lai, Y., Yao, D., Ung, C. O. L., & Hu, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1254398 · Cited by 28
“Pharmacological therapies are still categorized as a second-line auxiliary approach to treat obesity at designated obese stages or body mass index (BMI) levels with consideration of the occurrence of comorbidities (32, 33, 35 – 37).”
BackgroundKaplan, L. M., Gudzune, K. A., Ard, J. D., Kumar, R. B., Ahmad, N. N., Kan, H. J., Sims, T. J., Poon, J. L., King-Concialdi, K., Beusterien, K. M., et al. (2025) · Obesity · doi:10.1002/oby.24290 · Cited by 24
“…a gap in the appreciation of neurobiological processes that can burden patients attempting to adhere to certain recommendations, especially for extended time periods, as well as a gap in the appreciation of guidelines for AOMs that support patients in adhering to nutritional recommendations [24].”
Obesity medications: what does the future look like?
Butsch, W. S. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000192 · Cited by 25
Chapman, J. L., Cayanan, E. A., Hoyos, C. M., Serinel, Y., Comas, M., Yee, B. J., WONG, K. K. H., Grunstein, R. R., & Marshall, N. S. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2439oc · Cited by 23
Imaging Metabolically Active Fat: A Literature Review and Mechanistic Insights
Frankl, J. A., Sherwood, A., Clegg, D. J., Scherer, P. E., & Öz, O. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215509 · Cited by 26
“Major professional society guidelines recommend pharmacotherapy as a treatment option for obesity (body mass index [BMI] >30 kg/m2) and overweight with a BMI >27 kg/m2 and associated comorbidities such as type 2 diabetes, obstructive sleep apnea, or hypertension [4,5].”
BackgroundGomes, D. L., Oliveira, D. D. A., Dutra, E. S., Pizato, N., & de Carvalho, K. M. B. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1963-5 · Cited by 27
The strategy of obesity management: the results of All-Russian observational program “Primavera”
Dedov, I. I., Mel'nichenko, G. A., & Romantsova, T. I. (2016) · Obesity and metabolism · doi:10.14341/omet2016136-44 · Cited by 29
Kawata, Y., Okuda, S., Hotta, N., Igawa, H., Takahashi, M., Ikoma, M., Kasai, S., Ando, A., Satomi, Y., Nishida, M., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.12.018 · Cited by 22
“Despite the increasing prevalence, few drugs have fully met doctors' and patients' needs in the management of obesity and NAFLD because of insufficient efficacy, cost, and safety concerns (Moscatiello et al., 2011; Apovian et al., 2015).”
BackgroundBadurdeen, D., Hoff, A. C., Barrichello, S. A., Hedjoudje, A., Itani, M. I., Farha, J., Abbarh, S., Adam, A., Singh, V. K., Ngamruengphong, S., et al. (2020) · Obesity Surgery · doi:10.1007/s11695-020-05117-8 · Cited by 24
Herbal nanotherapy: A new paradigm over conventional obesity treatment
Shende, P. K., & Narvenker, R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102291 · Cited by 29
György, J., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Winkler, G., & Wittmann, I. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.1 · Cited by 40
Current pharmacotherapies for obesity: A practical perspective
Golden, A. K. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12519 · Cited by 27
“…and other medications or weight-loss options pursued in patients who do not respond with at least a 5% weight loss after 12 weeks of therapy (Apovian et al., 2015; Jensen et al., 2014; Yumuk et al., 2015; see Prescribing Information for productspecific information; FDA, 2014a,b,c, 2015b,…”
BackgroundInfluentialComprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood
Simon, S. L., Phimphasone‐Brady, P., McKenney, K. M., Gulley, L. D., Bonny, A. E., Moore, J. M., Torres-Zegarra, C., & Cree‐Green, M. (2024) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(24)00019-1 · Cited by 31
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.10.001 · Cited by 26
“The Endocrine Society guidelines represent a paradigm shift by recommending pharmacologic and health-behaviour therapy to treat the weight first before addressing the obesity-related comorbidities (17).”
BackgroundMucuna pruriens treatment shows anti-obesity and intestinal health effects in obese rats
Tavares, R. L., de Vasconcelos, M. H. A., Dorand, V. A. M., Torres, E. U., Toscano, L. T., de Queiroz, R. T., Alves, A. F., Magnani, M., Guzmán‐Quevedo, O., & Aquino, J. D. S. (2021) · Food & Function · doi:10.1039/d0fo03261a · Cited by 26
Lohnberg, J. A., Salcido, L., Frayne, S. M., Mahtani, N., Bates, C., Hauser, M. E., & Breland, J. Y. (2021) · Obesity Science & Practice · doi:10.1002/osp4.550 · Cited by 24
Tondt, J., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100017 · Cited by 24
“…“ -tides ” ) May decrease body weight [12 – 15] Sodium glucose co-transporter 2 inhibitors (e.g., “ - fl ozins ” ) May decrease body weight [12,15, 16] Alpha glucosidase inhibitors (e.g., acarbose, miglitol) May decrease body weight [12,13, 15] Amylin mimetic (pramlintide) May decrease body…”
BackgroundInfluentialA Comparison of New Pharmacological Agents for the Treatment of Obesity
Nuffer, W. A., Trujillo, J. M., & Megyeri, J. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016634351 · Cited by 24
“Both the American Heart Association/American College of Cardiology/The Obesity Society (AHA/ACC/TOS) guidelines and the Endocrine Society guidelines recommend that medications be considered as an adjunct to lifestyle or behavioral interventions in patients with a BMI ≥30 kg/m(2) or patients with a BMI ≥27 kg/m(2) plus…”
BackgroundAcute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave®)
Singh, P., Cassel, K. P., Moscati, R. M., & Eckersley, D. (2017) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2016.11.034 · Cited by 21
Kim, C. O., Kim, Y. N., & Lee, D. (2019) · Nutrients · doi:10.3390/nu11071513 · Cited by 21
“These medications are approved only for patients with a body mass index (BMI) of ≥30 kg/m2 or ≥27 kg/m2, with at least one obesity-related co-morbidity [6,7].”
BackgroundWong, J., Chan, K. Y., & Lo, K. K.-H. (2021) · Obesity Reviews · doi:10.1111/obr.13336 · Cited by 21
“Guidelines have recommended the continuation of weight loss medication only if 5% of body weight loss rate, which is often regarded as clinically meaningful weight loss rate, is achieved after 3 months.(17,45,46) SGLT-2 inhibitor monotherapy is unlikely to achieve such intensive weight loss in 12 weeks.”
BackgroundMethodNesto, R., Fain, R., Li, Y., & Shanahan, W. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1178590 · Cited by 20
“For patients who are overweight or obese, the Endocrine Society Clinical Practice Guideline [26] recommends weight management before treating comorbidities.”
BackgroundTargeting the GDF15 Signalling for Obesity Treatment: Recent Advances and Emerging Challenges
Zhang, J., Sun, J., Li, J., & Xia, H. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70251 · Cited by 26
Sun, Y., Li, D., Zhao, L., Liu, X., Guan, K., Ma, Y., Wang, R., & Li, Q. (2025) · Journal of Dairy Science · doi:10.3168/jds.2024-26193 · Cited by 24
Sari, C., Seip, R. L., & Umashanker, D. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.588016 · Cited by 22
“Also, studies in rodents have shown increasing expression and secretion of growth differentiating factor 15 (GDF15) in hepatocytes leading to decreased appetite and subsequent weight loss (13).”
BackgroundAntiobesity drug therapy: An individualized and comprehensive approach
Mauer, Y., Parker, M., & Kashyap, S. R. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20080 · Cited by 27
“7,30 The clinician should also eliminate or replace the patient’s current obesity-inducing medications with more favorable ones whenever appropriate.”
BackgroundThe beneficial effects of genetically engineered Escherichia coli Nissle 1917 in obese C57BL/6J mice
Ma, J., Wang, J., Xu, L., Liu, Y., & Gu, J. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01073-8 · Cited by 22
“Obesity can lead to a range of diseases, such as type 2 diabetes, cardiovascular disease, nonalcoholic fatty liver disease, sleep apnea, asthma, and high blood pressure [4, 5].”
BackgroundRuze, R., Chen, Y., Xu, R., Song, J., Yin, X., Wang, C., & Xu, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188844 · Cited by 23
Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?
Lewis, K. H., Gudzune, K. A., & Ard, J. D. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00546-9 · Cited by 25
“Additionally, because phentermine can increase heart rate and blood pressure acutely, there are concerns that longer-term use may increase the risk of cardiovascular events [5, 13].”
InfluentialChang, H., Chen, S.-Y., Lin, J., Chen, Y., Chen, Y., Liu, Y., & Yen, G. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c01226 · Cited by 24
Treatment Options for Poor Responders to Bariatric Surgery
Lee, P. C., Dixon, J. B., Sim, P. Y., & Lim, C. H. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00381-2 · Cited by 21
Differentially Expressed Genes and Enriched Signaling Pathways in the Adipose Tissue of Obese People
Lu, Z., Meng, L., Sun, Z., Shi, X., Shao, W., Zheng, Y., Yao, X., & Song, J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.620740 · Cited by 22
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
“She serves on speaker bureaus for Eli Lilly, International Diabetes Canada, Medical Press, Novo Nordisk, and ViiV.”
BackgroundInfluentialPreoperative thyroid function and weight loss after bariatric surgery
AMTCO Group, Neves, J. S., Souteiro, P., Oliveira, S. C., Pedro, J. M. P., Magalhães, D. M. D. S., Guerreiro, V. A., Costa, M. M., Bettencourt‐Silva, R., Santos, A. C., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0071-8 · Cited by 24
Outdoor environment and obesity: A review of current evidence
Polyzou, E. A., & Pοlyzos, S. A. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100331 · Cited by 21
MicroRNA Modulation by Dietary Supplements in Obesity
Filardi, T., Sabato, C., Lubrano, C., Santangelo, C., Morano, S., Lenzi, A., Migliaccio, S., Ferretti, E., & Catanzaro, G. (2020) · Biomedicines · doi:10.3390/biomedicines8120545 · Cited by 19
“Besides lifestyle modifications, several pharmacologic agents are currently available for obesity management, even though conflicting results in terms of efficacy, durability of weight control, and adverse effects have been reported in clinical trials [7].”
BackgroundCuda, S. E., Censani, M., Kharofa, R. Y., O’Hara, V. M., Conroy, R., Williams, D. R., Paisley, J., Browne, A. F., Karjoo, S., & Browne, N. T. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100048 · Cited by 22
“…the hypothalamus, leading to the release of norepinephrine while top-iramate's actions are multimodal; enhances γ -Aminobutyric acid (GABA) release while inhibiting α -amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) and N-methyl-D -aspartic acid or N-methyl-D -aspartate (NMDA) [63].”
BackgroundInfluentialOyetoro, R. O., Wiemer, L., Bardhi, O., Louis, M., & Jacob, R. (2023) · Advances in Medicine · doi:10.1155/2023/2955772 · Cited by 22
“In obese individuals, the excess accumulation of fat in adipocytes releases proinfammatory cytokines that inhibit the secretion of adiponectin (an insulin-secreting molecule) [44, 45].”
Game changers: do new medications make lifestyle‐based treatment of obesity obsolete?
Lewis, K. H., Moore, J. B., & Ard, J. D. (2023) · Obesity · doi:10.1002/oby.23962 · Cited by 20
Obesity and type 2 diabetes: can we find a compromised treatment solution?
Galstyan, G. R., Shestakova, E. A., & Sklyanik, I. A. (2017) · Diabetes Mellitus · doi:10.14341/dm8726 · Cited by 26
dos Santos, U. P., Tolentino, G. S., Morais, J. S., Souza, K. D. P., Estevinho, L. M., & dos Santos, E. L. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2976985 · Cited by 26
“Some of the drug alternatives to treat obesity are related to the inhibition of enzymes involved in fat digestion and absorption [106].”
BackgroundSafety and efficacy of naltrexone for weight loss in adult patients – a systematic review
Kułak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2021) · Archives of Medical Science · doi:10.5114/aoms.2020.96908 · Cited by 24
“These directives were created by the Endocrine Society (a task force of experts), the European Society of Endocrinology and the Obesity Society [11].”
BackgroundBarocrinology: The Endocrinology of Obesity from Bench to Bedside
Kalra, S., Kapoor, N., Bhattacharya, S., Aydin, H., & Coetzee, A. (2020) · Medical Sciences · doi:10.3390/medsci8040051 · Cited by 22
“Medications prescribed and their treatment profile [56,57].”
BackgroundBays, H. E., Burridge, K., Richards, J., & Fitch, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100039 · Cited by 18
“An illustrative recommendation for patients with obesity treated with AOMs is follow-up is at least monthly for the fi rst 3 months, and then at least every 3 months in all patients using AOMs [21].”
MethodJense, M. T. F., Palm‐Meinders, I. H., Sanders, B., Boerma, E.-J. G., & Greve, J. W. M. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06573-8 · Cited by 22
Pražnikar, Z. J., Mohorko, N., Gmajner, D., Kenig, S., & Petelin, A. (2023) · Foods · doi:10.3390/foods12112122 · Cited by 24
“Pharmacotherapy has emerged as an alternative or complementary therapy when lifestyle changes do not result in the desired weight loss [10].”
BackgroundÜner, B., & Macit, M. S. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01365-7 · Cited by 27
RetractedLiraglutide: An Injectable Option for the Management of Obesity
Clements, J. N., & Shealy, K. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015586806 · Cited by 23
“%) have comparable prevalence rates among this ethnic group.2 In 2008, the medical costs associated with obesity were estimated to be $147 billion, compared with $78.5 billion in 1998.3 In 2006, approximately $1400 more was spent on medical care for patients with obesity when compared with those of normal weight.3 Sev…”
BackgroundMethodInfluentialThe case for stepped care for weight management after bariatric surgery
Kalarchian, M. A., & Marcus, M. D. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.07.023 · Cited by 27
Balan, D., Chan, K., Murugan, D. D., AbuBakar, S., & Wong, P. (2018) · Phytotherapy Research · doi:10.1002/ptr.6065 · Cited by 22
“provide additional benefit in ameliorating comorbidities and promoting adherence to behavior modifications, which in turn may improve physical functions for greater physical activity (Apovian et al., 2015).”
BackgroundLeggett, C. B., Desalermos, A. P., Brown, S. D., Lee, E., Proudfoot, J. A., Horgan, S., Gupta, S. N., Grunvald, E. L., Ho, S. B., & Zarrinpar, A. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0207-x · Cited by 18
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
Caixàs, A., Villaró, M., Irigoyen, C. A., Montalvá, J.-C., Lecube, A., Fernández-García, J.-M., Corio, R., Bellido, D., Llisterri, J. L., & Tinahones, F. J. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.10.010 · Cited by 21
Understanding the pathophysiologic pathways that underlie obesity and options for treatment
Kumar, R. B., Srivastava, G., Reid, T. J., & Aronne, L. J. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1991310 · Cited by 25
“Not all people living in an obesogenic environment become obese, which suggests that there are underlying genetic mechanisms in place [17].”
BackgroundMethodInfluentialSelf-citationKozica, S. L., Lombard, C. B., Harrison, C. L., & Teede, H. J. (2016) · Implementation Science · doi:10.1186/s13012-016-0521-4 · Cited by 22
“Background Treatment of established obesity via lifestyle interventions is challenging with poor engagement, high costs, and minimal sustainability [1, 2].”
BackgroundQuinoa and Chia Modulate AMPK/PPAR-ɣ Signaling in High-Fat Diet–Induced Obesity Rat Model
Omran, N. H., El-Bahy, A. A. Z., Hosny, H. T. A., & Handoussa, H. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00388-5 · Cited by 17
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Moss, L., Laudenslager, M., Steffen, K. J., Sockalingam, S., & Coughlin, J. W. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00598-5 · Cited by 23
“…induced weight gain (AIWG) recommend change in regimen to a more weight neutral medication when possible and/or behavioral weight loss (BWL) intervention as first-line options, with secondary consideration of adjunct pharmacological treatment, followed by metabolic and bariatric surgery [77, 78].”
Linetzky, B., Sattar, N., Verma, S., Krumholz, H. M., Xie, C. C., Hoffmann, H. T., Zimner-Rapuch, S., Torcello-Gómez, A., & Stefanski, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02623 · Cited by 17
Ard, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 28
“13,14 These treatment guidelines were published in 2015 when highly effective OMMs were not yet available.”
Clements, J. N., Albanese, N. P., D’Souza, J. J., Misher, A., Reece, S. W., Trujillo, J. M., & Whitley, H. P. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1512 · Cited by 22
“Current practice guidelines point out that patients can gain as much as 10 kg in the first 3 to 6 months of therapy with sulfonylureas, thiazolidinediones, or insulin.(49)”
BackgroundMethodInfluentialWen, Z. G., Zhang, Q. Q., Zhang, L. L., Shen, M. F., Huang, Y., & Zhao, L. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964495 · Cited by 22
“At present, surgery has also been proven to be effective for severely obese people (Apovian et al., 2015; LeBlanc et al., 2018).”
BackgroundPrevalence of genetic causes of obesity in clinical practice
Tamaroff, J. G., Williamson, D., Slaughter, J. C., Xu, M. J., Srivastava, G., & Shoemaker, A. H. (2023) · Obesity Science & Practice · doi:10.1002/osp4.671 · Cited by 20
“The Endocrine Society clinical practice guidelines for management of adult obesity recommend identification of contributing factors such as genetics but there is no guidance on when to pursue genetic testing.(18) In clinical practice, it may be challenging to ascertain a history of early‐onset obesity as most patients…”
MethodRyan, D. H. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.001 · Cited by 17
Self-citationElizalde-Romero, C. A., Leyva‐López, N., Contreras‐Angulo, L. A., de León, R. C.-P., Rodríguez-Anaya, L. Z., León‐Félix, J., Heredia, J. B., Beltrán-Ontiveros, S. A., & Gutiérrez‐Grijalva, E. P. (2024) · Receptors · doi:10.3390/receptors3030017 · Cited by 23
“Nonetheless, for some patients, other measures are necessary, so the treatment includes anti-obesity pharmacotherapy [7].”
BackgroundNext Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
Wharton, S., & Serodio, K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0590-z · Cited by 19
Excess Gestational Weight Gain in Pregnancy and the Role of Lifestyle Intervention
Goldstein, R. F., Thangaratinam, S., Boyle, J. A., & Teede, H. J. (2016) · Seminars in Reproductive Medicine · doi:10.1055/s-0036-1583531 · Cited by 26
Kumar, R. B., & Aronne, L. J. (2016) · Techniques in Gastrointestinal Endoscopy · doi:10.1016/j.tgie.2016.11.003 · Cited by 19
Self-citationWeight loss drugs and lifestyle modification: Perceptions among a diverse adult sample
Xing, S., Sharp, L. K., & Touchette, D. R. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2016.11.004 · Cited by 20
NATIONAL CLINICAL RECOMMENDATIONS FOR OBESITY: CONCEPT AND PROSPECTS
Nedogoda, S. V., Barykina, I. N., & Salasyuk, A. S. (2017) · Journal of Volgograd State Medical University · doi:10.19163/1994-9480-2017-1(61)-134-140 · Cited by 17
“В течение последних двух лет появились документы AHA/ACC/TOS Guidelines (2013, [18]), AACE Advanced Framework (2014, [13]), ASBP Algorithm (2014, [28]), The Endocrine Society Guidelines Pharmacologic Management of Obesity (2015, [9]), которые касаются проблемы ожирения, но существенно различаются между собой по целям,…”
ASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management
ASGE EndoVators Task Force, Ryou, M. K., McQuaid, K. R., Thompson, C. C., Edmundowicz, S. A., & Mergener, K. (2017) · Surgical Endoscopy · doi:10.1007/s00464-017-5934-x · Cited by 17
Noriea, A. H., Patel, F. N., Werner, D. A., & Peek, M. E. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0990-8 · Cited by 19
Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
Cope, R. J., Fischetti, B., Kavanagh, R., Lepa, T. M., & Sorbera, M. A. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2342 · Cited by 17
Brown, J. C., Harhay, M. O., & Harhay, M. N. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1308-8 · Cited by 18
“More recently, various pharmacotherapies have been developed as adjuncts to lifestyle modification to promote weight loss [35].”
BackgroundUnmet needs in obesity management: From guidelines to clinic
Ritten, A., & LaManna, J. B. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12507 · Cited by 24
Pediatric Obesity: Influence on Drug Dosing and Therapeutics
Ameer, B., & Weintraub, M. A. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1092 · Cited by 19
Pharmacotherapeutic strategies for treating hypertension in patients with obesity
Carnagarin, R., Matthews, V. B., Gregory, C., & Schlaich, M. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1458092 · Cited by 21
High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211053867 · Cited by 16
Zhang, S., Sun, B., Sun, L., Zou, S., & Chen, Q. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01952-x · Cited by 24
“It has been proven to be effective in reducing body weight and improving glycemic control and cholesterol levels, thereby facilitating the management of metabolic syndrome [11].”
Torrente‐Sánchez, M. J., Márquez, M. F., Estébanez-Ferrero, B., Jiménez‐Lasserrotte, M. D. M., Ruiz‐Muelle, A., Ventura‐Miranda, M. I., Dobarrio‐Sanz, I., & Granero‐Molina, J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126530 · Cited by 16
Impact of Adjunctive Pharmacotherapy With Intragastric Balloons for the Treatment of Obesity
Mehta, A., Shah, S. L., Dawod, E., Hajifathalian, K., Kumar, R. B., Igel, L. I., Saunders, K. H., Kumbhari, V., Farha, J., Badurdeen, D., et al. (2021) · The American Surgeon · doi:10.1177/00031348211038579 · Cited by 17
“The Food and Drug Administration (FDA) has approved five pharmacologic agents for weight loss: phentermine, orlistat, phentermine/topiramate, liraglutide, and naltrexone/bupropion.(17) The use of these anti-obesity medications as adjunctive treatments to augment and maintain weight loss following IGB therapy has been…”
BackgroundSelf-citationArmstrong, A. A., Berger, M., & Al-Safi, Z. A. (2022) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000794 · Cited by 19
Serious games and eating behaviors: A systematic review of the last 5 years (2018–2022)
Limone, P., Messina, G., & Toto, G. A. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.978793 · Cited by 29
“Specifically, among them, we can find diet and lifestyle interventions (17), drugs for weight reduction (18), balancing prescription of medications that cause weight gain (18) and surgical intervention (19).”
BackgroundA Women's health perspective on managing obesity
Johnson, V. R., Anekwe, C. V., Bell-Washington, T., Chhabria, S. M., Tu, L., & Stanford, F. C. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.04.007 · Cited by 19
Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity
Barrea, L., Boschetti, M., Gangitano, E., Guglielmi, V., Verde, L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00602-y · Cited by 21
“Both components of this medication have been used for other medical conditions since the 1980s, while the association was approved by the FDA and EMA in 2014 and 2015 [ 22].”
Li, Y., Liu, X., Fan, Y., Yang, B., & Huang, C. (2017) · PeerJ · doi:10.7717/peerj.3305 · Cited by 18
Pharmacological Interventions for Obesity: Current and Future Targets
Bocarsly, M. E. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0204-0 · Cited by 21
Association of organic food consumption with obesity in a nationally representative sample
Gosling, C. J., Goncalves, A., Ehrminger, M., & Valliant, R. L. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520003189 · Cited by 17
“Numerous studies have shown that drug use is associated with weight gain (e.g. Apovian et al.(49)); to the best of our knowledge, no study has yet examined whether the prevalence of drug use differs depending on organic food consumption.”
BackgroundRamos, D., Freitas, J. M., Muñoz, R. A. A., & Richter, E. M. (2021) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2021.115028 · Cited by 16
Obesity pillars roundtable: Phentermine – Past, present, and future
Bays, H. E., Lazarus, E., Primack, C., & Fitch, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100024 · Cited by 22
“General considerations in prescribing phentermine via telehealth [50].”
BackgroundInfluentialBazan, I. S., & Fares, W. H. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.049 · Cited by 17
An update on naltrexone/bupropion extended-release in the treatment of obesity
Saunders, K. H., Igel, L. I., & Aronne, L. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1244527 · Cited by 21
Self-citationAdvanced Practice Nursing student knowledge in obesity management: A mixed methods research study
Fruh, S., Golden, A. K., Graves, R., Hall, H. R., Minchew, L. A., & Williams, S. G. (2019) · Nurse Education Today · doi:10.1016/j.nedt.2019.03.006 · Cited by 19
“Based on National Guidelines, at Which BMI Level Would a Healthcare Provider Initiate Therapy with Anti-Obesity Medications? The Endocrine Society recommends starting anti-obesity medications when an individual has a BMI ≥ 27 with one or more comorbidities or ≥ 30 without comorbidities (Apovian et al., 2015).”
BackgroundMethodInfluentialElhag, W., El Ansari, W., Abdulrazzaq, S., Elsherif, M., & Mustafa, I. (2019) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2019.07.024 · Cited by 15
Dou, P., Zhang, T.-T., Xu, Y., Xue, Q., Zhang, Y., Shang, J., & Yang, X.-L. (2024) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303286777240223074922 · Cited by 15
Arya, A., Nahar, L., Khan, H. U., & Sarker, S. D. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.02.006 · Cited by 22
Practical Approaches to Treating Obesity: Patient and Healthcare Professional Perspectives
O'Shea, D. B., Kahan, S. I., Lennon, L., & Breen, C. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01748-0 · Cited by 19
Edible insects and their potential anti-obesity effects: a review
Lange, K. W., & Nakamura, Y. K. (2023) · Food Science of Animal Products · doi:10.26599/fsap.2023.9240008 · Cited by 18
Real-world primary nonadherence to antiobesity medications
Kan, H. J., Bae, J. P., Dunn, J. P., Buysman, E. K., Gronroos, N. N., Swindle, J. P., Bengtson, L. G. S., & Ahmad, N. Y. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.23083 · Cited by 17
Metadata
- Authors
- Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D.
- Affiliations
- Pennington Biomedical Research Center (US)
- Cornell University (US)
- Denver Health Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Geisinger Health System (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 342-362
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2109366467
- Semantic Scholar
- 32e063efbad03793d5b9794138fe9a8f9b3a4650
- Cited by
- 1,347
- References
- 154
- Citations by year
- 2026: 109 · 2025: 128 · 2024: 157 · 2023: 134 · 2022: 112 · 2021: 129 · 2020: 132 · 2019: 98 · 2018: 91 · 2017: 102 · 2016: 95 · 2015: 55
- FWCI
- 82.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, anti-obesity drugs, weight loss, lifestyle modification, obesity-related comorbidities, medication-induced weight gain, drug prescribing, chronic disease medications
- MeSH terms
- Endocrinology, Humans, Obesity, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.